Promising #ESMO2026 data for JNJ-6143, a first-in-class oral RIPTAC in heavily pretreated #mCRPC.

PSA50 77% | PSA90 48% | ORR 69%

Encouraging activity, including in high-risk molecular subgroups. Early phase I, but one to watch.

#ProstateCancer